ENTRY       D10620                      Drug
NAME        Bimagrumab (JAN/USAN/INN)
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT SSYINWVRQA PGQGLEWMGT INPVSGSTSY
            AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARGG WFDYWGQGTL VTVSSASTKG
            PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
            SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP EAAGGPSVFL
            FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV
            VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSREEMTKNQ
            VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV
            FSCSVMHEAL HNHYTQKSLS LSPGK
            (Light chain)
            QSALTQPASV SGSPGQSITI SCTGTSSDVG SYNYVNWYQQ HPGKAPKLMI YGVSKRPSGV
            SNRFSGSKSG NTASLTISGL QAEDEADYYC GTFAGGSYYG VFGGGTKLTV LGQPKAAPSV
            TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV KAGVETTTPS KQSNNKYAAS
            SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS
            (Disulfide bridge: H22-H96, H142-H198, H218-L216, H224-H'224, H227-H'227, H259-H319, H365-H423, H'22-H'96, H'142-H'198, H'218-L'216, H'259-H'319, H'365-H'423, L22-L90, L139-L198, L'22-L'90, L'139-L'198)
  TYPE      Peptide
EFFICACY    Activin receptor type-2 modulator
  TYPE      Monoclonal antibody
COMMENT     Prevention and treatment of muscle wasting
TARGET      ACVR2A [HSA:92] [KO:K04670]
            ACVR2B [HSA:93] [KO:K13596]
BRITE       Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor serine/threonine kinases (RSTK)
               TGFBR2 family
                ACVR2A
                 D10620  Bimagrumab (JAN/USAN/INN)
                ACVR2B
                 D10620  Bimagrumab (JAN/USAN/INN)
DBLINKS     CAS: 1356922-05-8
            PubChem: 254741581
///
